Chonluten
Also known as: Glu-Asp-Gly · EDG · Khavinson lung peptide bioregulator · Chonluten (Cytogen series) · bronchogen (informal vendor synonym)
Research focus
Respiratory / bronchial-pulmonary tissue (bronchial epithelium and alveolar/lung cells).
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
No Human Data
Origin
Chonluten is a synthetic short-peptide ("Cytogen") attributed to the research group of Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. The broader program dates to the 1970s-1980s, when Khavinson and colleagues first prepared organ-specific peptide extracts from animal tissues (for the respiratory line, preparations derived from calf tracheal mucosa and lung parenchyma processed by the same method used for the thymic preparation Thymalin). According to PubMed, that early natural-extract respiratory work appears as far back as 1993 (Khavinson VKh et al., on tracheal-mucosa and lung-parenchyma peptides in experimental influenza; [DOI not assigned / PMID 8067076]). Chonluten represents the later, fully synthetic short-peptide version of that lung/bronchial line, designed to reproduce the proposed tissue-specific activity in a defined, manufacturable molecule. It is marketed within the same Cytogen family as Epitalon (pineal), Vilon, and Thymogen, and is positioned for respiratory/bronchial "support." Note: the only peer-reviewed English-language paper that names Chonluten directly describes it specifically as a tripeptide "derived from bronchial epithelial cells" (Avolio F et al., 2022; [DOI](https://doi.org/10.3390/ijms23073607)).
Plain-language summary
Chonluten is a lab-made three-amino-acid peptide (Glu-Asp-Gly) from the same Russian research program (the Khavinson group in St. Petersburg) that produced Epitalon. It is one of a family of "tissue-specific" peptides, and this one is aimed at the lungs and airways. The bottom line: there is almost no published research on Chonluten itself. The single peer-reviewed English-language study that names it was done in a dish, on cultured immune cells, not in people — it suggested the peptide can dial down some inflammation signals. Beyond that there are general review articles from the same group describing the idea that short peptides influence lung-cell genes, but no human trials, no dosing studies, and no independent confirmation that it does anything for breathing, lung disease, or respiratory health. Anything sold online as "Chonluten" is an unregulated research chemical, and the marketing claims run far ahead of the evidence.
Claimed mechanism (as reported)
The Khavinson group proposes that ultrashort peptides like Chonluten act as epigenetic "bioregulators": small enough to enter the cell and nucleus and reportedly interact with DNA, histones, and gene-promoter regions to modulate tissue-specific gene expression — in this case, genes linked to bronchial/lung epithelial differentiation and inflammation-modulating signaling. The most concrete published data point is in-vitro: in cultured human monocytes (THP-1), the Chonluten tripeptide reportedly inhibited LPS-stimulated TNF and IL-6 release, which the authors interpret as a proposed inflammation-modulating / TNF-tolerance effect (Avolio F et al., 2022; [DOI](https://doi.org/10.3390/ijms23073607)). This DNA-binding / epigenetic model is supported primarily by in-silico and in-vitro work from a single research group and remains an unproven hypothesis; no mechanism has been confirmed in human respiratory tissue.
Evidence summary
The published record specific to Chonluten is extremely thin. As of 2026, a PubMed search returns essentially one peer-reviewed English-language study that names and tests "Chonluten" directly, and it is an in-vitro experiment on a human monocyte cell line (not lung tissue, not animals, not humans). The remaining support is indirect: review and mechanism papers from the Khavinson group describing the general concept that short peptides regulate gene expression and lung-cell differentiation, plus decades-old work on natural tracheal/lung peptide extracts that predate the synthetic molecule. There are no randomized controlled trials, no published human respiratory studies, and no independent replication of any Chonluten-specific finding in peer-reviewed English-language literature. Evidence is graded No Human Data: the few real data points are preclinical and single-group, and the marketed respiratory claims are not supported by published human evidence.
What the research reports
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Grade DAvolio F, Martinotti S, Khavinson VKh, Esposito JE, Mironova E, Trofimova S et al. · International Journal of Molecular Sciences · 2022
Reported finding: Among five Khavinson peptides tested, the Chonluten tripeptide — described as derived from bronchial epithelial cells — reportedly inhibited TNF and IL-6 production in LPS-stimulated, PMA-differentiated monocytes and reduced monocyte adhesion to activated endothelium in vitro, interpreted by the authors as a proposed inflammation-modulating / TNF-tolerance effect.
Sample: In-vitro cell-culture experiments (no organisms; replicate cultures, exact n not standardized)
Methodology: D — single in-vitro study, human monocyte (THP-1) cell line only; no animal or human data; co-authored by the originating research group
Limitations: In-vitro only; immune (monocyte) cells, not lung/airway tissue; effects shown at selected concentrations; originating group is a co-author; no dose-response in vivo and no clinical correlate. Says nothing about efficacy in living lungs or people.
Peptide Regulation of Cell Differentiation (review)
Grade CKhavinson V, Linkova N, Diatlova A, Trofimova S · Stem Cell Reviews and Reports · 2020
Reported finding: Summarizes the group's hypothesis that specific short peptides direct tissue-specific differentiation; states that the lung-associated peptide AEDL (and KEDW for pancreas) reportedly induce lung/pancreatic cell differentiation in culture, framing the proposed mechanism for the respiratory peptide line that includes Chonluten.
Sample: Not applicable (review)
Methodology: C — narrative review from the originating group; summarizes prior in-vitro/preclinical claims, not primary efficacy data
Limitations: Review, not an experiment; lung claims rest on the group's own unreplicated in-vitro work; describes the tetrapeptide AEDL rather than the Glu-Asp-Gly tripeptide marketed as Chonluten, so it does not directly validate the sold compound; no human data.
Peptides: Prospects for Use in the Treatment of COVID-19 (review)
Grade CKhavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R · Molecules · 2020
Reported finding: Proposes that several Khavinson immunomodulatory/bronchoprotective short peptides could, in theory, blunt cytokine release and exert lung-protective effects relevant to respiratory illness; explicitly states such efficacy is not yet proven.
Sample: Not applicable (review)
Methodology: C — speculative narrative review from the originating group; mechanistic hypothesis, no trial data
Limitations: Hypothesis-generating only; no clinical or in-vivo respiratory outcome data for Chonluten; authored by the originating group; the paper itself concedes clinical efficacy is unproven.
Protective effect of peptides from the thymus and tracheal mucosa in experimental respiratory influenza infection
Grade DKhavinson VKh, Kozhemiakin AL, Volgarev AP, Platonov VG · Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii (J. Microbiology, Epidemiology and Immunobiology) · 1993
Reported finding: Natural tracheal-mucosa and lung-parenchyma peptide preparations showed no direct antiviral activity but the tracheal-mucosa preparation reportedly enhanced immunological resistance to influenza in mice — historical precursor context for the later synthetic respiratory peptide line.
Sample: Mouse and chick-embryo influenza models (exact n not reported in abstract)
Methodology: D — early animal/chick-embryo study of natural tissue extracts (not the synthetic Chonluten tripeptide); in Russian
Limitations: Tests crude natural extracts, not the defined Glu-Asp-Gly synthetic; old, single-group, animal/embryo work; does not establish efficacy of Chonluten as sold; no human data.
Administration reported in studies
There is no established or validated human dosing for Chonluten. The single direct study was performed in cell culture, where the peptide was applied to cells at selected in-vitro concentrations — conditions that do not translate to a human dose. The historical Khavinson respiratory work used injected natural tissue-peptide preparations in animals, again not comparable to the synthetic tripeptide. Vendor materials in the research-chemical channel circulate informal subcutaneous "protocols," but these are not derived from any published human pharmacokinetic, dose-finding, or safety study and are not described in peer-reviewed literature. This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
No formal human safety data on Chonluten exist in the peer-reviewed English-language literature — there are no published clinical trials, no pharmacokinetic studies, and no systematic adverse-event reporting. The Khavinson group generally describes its short peptides as low-toxicity and free of reported side effects in their own preclinical work, but absence of reported harm in a handful of single-group, mostly in-vitro/animal studies is not the same as demonstrated human safety, and TPC does not treat it as such. Long-term effects, immunogenicity, effects in respiratory disease, and interactions are entirely uncharacterized in people. Material sold online is unregulated and not tested for identity, purity, sterility, or endotoxin by any independent authority; injectable use of such product carries the usual risks of unregulated, non-pharmaceutical preparations. Nothing here should be read as evidence that Chonluten is safe.
US legal status
Not FDA-approved for any use. Not on the FDA 503A compoundable bulk drug substances list, and not legally compoundable for human clinical use in the United States. Chonluten is sold online only as a "research chemical" / "not for human consumption" material; vendors in that channel are unregulated, and product identity, purity, and safety are not verified by TPC. It is not an approved drug, supplement, or therapy.
Open research questions
- ? Sequence/identity: is the marketed Chonluten truly the tripeptide Glu-Asp-Gly, or is the active lung peptide the related tetrapeptide AEDL (Ala-Glu-Asp-Leu) cited in the group's differentiation reviews? The one paper naming Chonluten confirms only that it is a tripeptide from bronchial epithelium — an authoritative residue-level structure needs independent confirmation.
- ? Does any effect exist beyond cell culture? The single direct study is in-vitro on monocytes, not lung tissue — are there any in-vivo or human respiratory data at all, from any group?
- ? Independent replication: can any laboratory outside the originating St. Petersburg group reproduce the reported anti-inflammatory or lung-differentiation effects?
- ? Human pharmacokinetics and safety: what happens to an ultrashort peptide like this when administered to people — absorption, stability, distribution, immunogenicity, long-term safety — none of which has been published?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →